News and media

Today, Amylyx announced that their Phase 3 PHOENIX trial, a global, 48-week, randomized, placebo-controlled study of AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine; also known as ALBRIOZA) in people living with ALS, did not meet its prespecified primary or secondary endpoints. It's understandable if this outcome has left us all feeling disheartened and discouraged. Now, more than ever,...